Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV

TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment with CABENUVA, oral cabotegravir (VOCABRIA) and oral rilpivirine (EDURANT®) should be administered for approximately one month to assess the tolerability of each therapy.CABENUVA, a co-packaged kit with two injectable medicines, offers people living with HIV a new approach for maintaining viral suppression.1 Click to Tweet: #BREAKING: The #FDA has approved another treatment option for people living with #HIV. Read full announcement here: http://...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

More News: Allergy & Immunology | Australia Health | Autoimmune Disease | Biochemistry | Brain | Breastfed | Canada Health | Cancer & Oncology | Carbamazepine | Cardiology | Cardiovascular | Chemistry | Child Development | Children | Chronic Pain | Clinical Trials | Conferences | Conjunctivitis | Depression | Dexamethasone | Drugs & Pharmacology | Epidemics | Epidemiology | Esomeprazole | Food and Drug Administration (FDA) | Gastroenterology | Genetics | Guillain-Barr Syndrome | Headache | Health Management | Heart | Hepatitis | Hepatitis B | Hepatitis Vaccine | Hypertension | Infectious Diseases | Insomnia | Internal Medicine | Ireland Health | Laboratory Medicine | Lansoprazole | Learning | Legislation | Liver | Liver Disease | Marketing | Migraine | Miscarriage | Neurology | Neuroscience | Nexium | Omeprazole | Pain | Pantoprazole | Pharmaceuticals | Phenobarbital | Phenytoin | Polymyositis | Postnatal Depression | Pregnancy | Prevacid | Prilosec | Profits and Losses | Protonix | Pulmonary Hypertension | Science | Skin | Sleep Disorders | Sleep Medicine | St John's Wort | Study | Suicide | Switzerland Health | Universities & Medical Training | Urology & Nephrology | USA Health | Vaccines | Virology | Warnings | Women